Safety and efficiency of using Omaulizumab in bronchial asthma

E. A. Strel’tsov, V. S. Demidov, L. V. Tsoy, M. E. Korovina, N. M. Razyschikova, А. E. Karzhauova

2019

Full text Open access: Gold Metadata (CSL-JSON)

DOI 10.21886/2219-8075-2019-10-2-6-12

Data confidence 70 medium

How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

This review reviews the efficacy and safety of omalizumab therapy in bronchial asthma using randomized trials of recent years. Mechanisms of the pathogenesis of bronchial asthma, the effectiveness of the drug and its side effects are discussed in detail. The effectiveness of omalizumab is considered at the following key research points: the need for inhaled glucocorticosteroids, the quality of patients’ life and the frequency of exacerbations. Systematic literature search was carried out on the databases Scopus, Web of Science, MedLine, elibrary and others.